Patent ID: 7919116

Claim:
A method of treating a human diabetic patient with an oral solid sustained release tablet of metformin hydrochloride, comprising: administering the sustained release tablet to the human diabetic patient once a day under fed conditions, wherein the sustained release tablet comprises (i) metformin hydrochloride and (ii) a sustained release material, wherein the tablet does not employ an expanding polymer, the sustained release tablet provides therapeutic plasma levels of said metformin to the human patient over a 12 to 24 hour period after administration; and the sustained release tablet exhibits the following in vitro dissolution profile when tested in a USP Type 2 apparatus at 75 rpms in 900 ml of a pH 7.5 phosphate buffer and 37° C.: 0-25% of the metformin is released after 2 hours; 10-45% of the metformin is released after 4 hours; 30-90% of the metformin is released after 8 hours; not less than 50% of the metformin is released after 12 hours; not less than 60% of the metformin is released after 16 hours and not less than 70% of the metformin is released after 20 hours.